2,020
Views
2
CrossRef citations to date
0
Altmetric
Editorial

In 30 years, gender-neutral vaccination eradicates oncogenic human papillomavirus (HPV) types while screening eliminates HPV-associated cancers

, , &
Pages 735-738 | Received 20 Sep 2021, Accepted 31 Mar 2022, Published online: 15 Apr 2022

References

  • World Health Organisation, WHO. WHO Director-General calls for all countries to take action to help end the suffering caused by cervical cancer. 2018 [cited 2022 Mar 3]. Available from: https://www.who.int/reproductivehealth/call-to-action-elimination-cervical-cancer/en
  • IARC. Monographs on the evaluation of carcinogenic risks to human. Lyon France: IARC; 2007. Vol. 90. 1–637.
  • Bruni L, Saura-Lázaro A, Montoliu A, et al. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019. Prev Med. 2021;144:106399.
  • Lehtinen M, Baussano I, Paavonen J, et al. Eradication of human papillomavirus and elimination of HPV-related diseases – scientific basis for global public health policies. Exp Rev Vaccines. 2019;18(2):153–160.
  • Vänskä S, Luostarinen T, Baussano I, et al., Vaccination with moderate coverage eradicates oncogenic Human Papillomaviruses if a gender-neutral strategy is applied. J Infect Dis. 222(6): 948–956. 2020.
  • Gray P, Kann H, Pimenoff VN, et al. HPV seroprevalence in pregnant women following gender-neutral and girls-only vaccination programs in Finland. PLoS Med. 2021;18:e1003588.••Randomized trial evidence that already low to moderate coverage gender-neutral HPV vaccination provides herd effect against HPV16.
  • Brisson M, Kim JJ, Canfell J, et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020;395:575–590. •Another dynamic transmission model suggests 100 years lag time for complete herd effect from girls-only HPV vaccination with 90% coverage.
  • Luostarinen T, Apter D, Dillner J, et al. Vaccination protects against invasive HPV-associated cancer. Int J Cancer. 2018;142:2186–2187.
  • Bi D, Apter D, Eriksson T, et al. Safety of the human papillomavirus (HPV)-16/18 AS04 adjuvanted vaccine in adolescents: end-of-study results from a community-randomized study. Human Vaccines Immunother. 2020;16:1392–1402.
  • Kalliala I, Eriksson T, Hokkanen M, et al. Reduced preterm birth rate after bivalent HPV vaccination in Finland. Prev Med. 2021;146:106473.
  • Malmqvist E, Natunen K, Lehtinen M, et al. Just implemention of HPV vaccination in developed countries. J Med Ethics. 2012;38:247–249.
  • Harper D, Nieminen P, Paavonen J, et al. Cervix cancer incidence can increase despite HPV vaccination. Lancet Infect Dis. 2010;10:594–595.
  • Ryser MD, Rositch A, Gravitt PE. Modeling of US human papillomavirus (HPV) seroprevalence by age and sexual behavior indicates an increasing trend of HPV infection following the sexual revolution. J Infect Dis. 2017;216:604–611.
  • Richardson LA, Tota J, Franco EL. Optimizing technology for cervical cancer screening in high-resource settings. Expert Rev Obstet Gynecol. 2011 May;6(3):343–353.
  • El-Zein M, Richardsson L, Franco E. Cervical cancer screening of HPV vaccinated populations: cytology, molecular testing, both or none. J Clin Virol. 2016;76:S62–68.
  • Bonde J, Floore A, Ejegod D, et al., Methylation markers FAM19A4andmiR124 −2as triage strategy for primary human papillomavirus screen positive women: a large European multicenter study. Int J Cancer. 148(2): 396–405. 2021.
  • Louvanto K, Eriksson M, Elfström KM, et al. Effectiveness of screening in human papillomavirus vaccinated women. Int J Cancer. 2020;147:440–447.
  • ClinicalTrials.gov. Effectiveness of cervical screening in HPV vaccinated women. 2014 [cited 2022, Mar 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT02149030?term=NCT02149030&draw=2&rank=1
  • ClinicalTrials.gov. Effectiveness of cervical screening in unvaccinated, herd effect protected women (HPV400) (HPV400). 2021 [cited 2022, Mar 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT04755517?term=NCT04755517&draw=2&rank=1
  • Centers for Disease Control and Prevention. CDC. Cancer data and Statistics. 2021 [cited 2022, Mar 21]. Available from: https://www.cdc.gov/cancer/dcpc/data
  • NORDCAN 2.0. Database version 9.0 accessed on 11/07/2021 (Figure 2), 09/09/2021 (table) 11 07 2021. https://nordcan.iarc.fr/en

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.